Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.65 |
| ▸ | F3 | P13726 | 1/20 | 0.65 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.61 |
| ▸ | PYGL | P06737 | 1/20 | 0.52 |
| ▸ | NHERF1 | O14745 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30457940 | 1.00 | F7 (0.65) | F7F3NR4A2PYGLNHERF1 | |
| SCHEMBL24067322 | 0.88 | F7 (0.69) | F7F3NR4A2PYGLNHERF1 | |
| SCHEMBL25261694 | 0.84 | NR4A2 (0.62) | NR4A2ALDH1A1KMT2A | |
| SCHEMBL26261524 | 0.83 | NR4A2 (0.62) | F7F3NR4A2PYGLNHERF1 | |
| SCHEMBL26261554 | 0.83 | NR4A2 (0.62) | F7F3NR4A2PYGLNHERF1 | |
| SCHEMBL25259281 | 0.83 | NR4A2 (0.62) | F7F3NR4A2PYGLNHERF1 | |
| SCHEMBL30457844 | 0.83 | NR4A2 (0.62) | F7F3NR4A2PYGLNHERF1 | |
| SCHEMBL25305847 | 0.82 | KDM4E (0.55) | NR4A2ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL25306279 | 0.82 | NR4A2 (0.60) | F7F3NR4A2PYGLNHERF1 | |
| SCHEMBL25742072 | 0.80 | NR4A2 (0.58) | F7F3NR4A2PYGLNHERF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444283-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-08-17 | — | — | US | disclosed |
| EP-4214192-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | Tactogen Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023107715-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107715-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2022061242-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2022-03-24 | — | — | WO | disclosed |
| EP-0259085-B1 | 2-GUANIDINO-4-ARYLTHIAZOLES FOR TREATMENT OF PEPTIC ULCERS | PFIZER INC. (US) | 1991-08-21 | — | — | EP | disclosed |
| US-5026715-A | 2-guanidino-4-arylthiazoles for treatment of peptic ulcers | PFIZER INC. (US) | 1991-06-25 | — | — | US | disclosed |
| EP-0259085-A1 | 2-Guanidino-4-arylthiazoles for treatment of peptic ulcers | PFIZER INC. (US) | 1988-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257347-A1 | ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | HTR6, TPH2, TPH1 | F7 1035/4885F3 2087/4885NR4A2 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.